Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1193226/full |
| _version_ | 1797806319591227392 |
|---|---|
| author | Neal M. Dixit Ezra A. Amsterdam |
| author_facet | Neal M. Dixit Ezra A. Amsterdam |
| author_sort | Neal M. Dixit |
| collection | DOAJ |
| first_indexed | 2024-03-13T06:05:33Z |
| format | Article |
| id | doaj.art-a24284652a744a3e92a2502bdee1126c |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-13T06:05:33Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-a24284652a744a3e92a2502bdee1126c2023-06-12T04:35:13ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-06-011010.3389/fcvm.2023.11932261193226Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trialsNeal M. DixitEzra A. Amsterdamhttps://www.frontiersin.org/articles/10.3389/fcvm.2023.1193226/fullguideline-directed medical therapyheart failurerevascularizationcardiomyopathycoronary artery bypass surgerypercutaneous coronary intervention |
| spellingShingle | Neal M. Dixit Ezra A. Amsterdam Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials Frontiers in Cardiovascular Medicine guideline-directed medical therapy heart failure revascularization cardiomyopathy coronary artery bypass surgery percutaneous coronary intervention |
| title | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_full | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_fullStr | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_full_unstemmed | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_short | Should GDMT be prioritized over revascularization in new onset HFrEF? Potential lessons from the REVIVED-BCIS2 and STRONG-HF trials |
| title_sort | should gdmt be prioritized over revascularization in new onset hfref potential lessons from the revived bcis2 and strong hf trials |
| topic | guideline-directed medical therapy heart failure revascularization cardiomyopathy coronary artery bypass surgery percutaneous coronary intervention |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1193226/full |
| work_keys_str_mv | AT nealmdixit shouldgdmtbeprioritizedoverrevascularizationinnewonsethfrefpotentiallessonsfromtherevivedbcis2andstronghftrials AT ezraaamsterdam shouldgdmtbeprioritizedoverrevascularizationinnewonsethfrefpotentiallessonsfromtherevivedbcis2andstronghftrials |